Literature DB >> 11313093

Predictors of response to lithium augmentation in tricyclic antidepressant-resistant depression.

T Bschor1, B Canata, B Müller-Oerlinghausen, M Bauer.   

Abstract

BACKGROUND: The efficacy of lithium augmentation in therapy-resistant depression has been shown in a series of well-designed, placebo-controlled studies. However, little is known about the predictors of a good response to this treatment strategy.
METHODS: We retrospectively examined the predictive value of 20 demographic, clinical, biochemical and endocrinological variables using a two-step logistic regression. Seventy-one in-patients with depression refractory to tricyclic antidepressants had received lithium augmentation as part of a standardised treatment protocol.
RESULTS: Within 4 weeks 37 patients (52%) responded to lithium augmentation. Five variables with predictive value were found. Responders were more severely depressed according to the Bech-Rafaelsen Melancholia Scale. The duration of their index episode was shorter. Triiodothyronine serum levels were lower and neuroleptic co-medication and co-diagnosis of personality disorder were less frequent. LIMITATIONS: This was an open, retrospective study.
CONCLUSIONS: Severity of depression is a predictor of response to lithium augmentation. This result conflicts with recent studies but is similar to results found in studies of other pharmacological antidepressant strategies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11313093     DOI: 10.1016/s0165-0327(00)00211-1

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  8 in total

Review 1.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

Review 2.  [Twenty-five years of lithium augmentation].

Authors:  T Bschor; U Lewitzka; A Pfennig; M Bauer
Journal:  Nervenarzt       Date:  2007-11       Impact factor: 1.214

Review 3.  Role of lithium augmentation in the management of major depressive disorder.

Authors:  Michael Bauer; Mazda Adli; Roland Ricken; Emanuel Severus; Maximilian Pilhatsch
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

4.  Hypothalamic-pituitary-thyroid system activity during lithium augmentation therapy in patients with unipolar major depression.

Authors:  Tom Bschor; Christopher Baethge; Mazda Adli; Ute Lewitzka; Uta Eichmann; Michael Bauer
Journal:  J Psychiatry Neurosci       Date:  2003-05       Impact factor: 6.186

5.  Brief major depressive episode as an essential predictor of the Bipolar Spectrum Disorder.

Authors:  Amir Shabani; Fatemeh Zolfigol; Mehdi Akbari
Journal:  J Res Med Sci       Date:  2009-01       Impact factor: 1.852

6.  Poor response to treatment: beyond medication.

Authors:  César Carvajal
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

Review 7.  Can Atypical Antipsychotic Augmentation Reduce Subsequent Treatment Failure More Effectively Among Depressed Patients with a Higher Degree of Treatment Resistance? A Meta-Analysis of Randomized Controlled Trials.

Authors:  Hee Ryung Wang; Young Sup Woo; Hyeong Sik Ahn; Il Min Ahn; Hyun Jung Kim; Won-Myong Bahk
Journal:  Int J Neuropsychopharmacol       Date:  2015-03-13       Impact factor: 5.176

8.  Standardisation framework for the Maudsley staging method for treatment resistance in depression.

Authors:  Abebaw Fekadu; Jacek G Donocik; Anthony J Cleare
Journal:  BMC Psychiatry       Date:  2018-04-11       Impact factor: 3.630

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.